{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:19:24Z","timestamp":1778545164911,"version":"3.51.4"},"reference-count":25,"publisher":"Kurume Medical Journal","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kurume Med. J."],"published-print":{"date-parts":[[2019,6,30]]},"DOI":"10.2739\/kurumemedj.ms662007","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T22:11:05Z","timestamp":1623708665000},"page":"115-120","source":"Crossref","is-referenced-by-count":2,"title":["A Single-Arm Open-Label Clinical Trial on the Efficacy and Safety of Sirolimus for Epileptic Seizures Associated with Focal Cortical Dysplasia Type II: A Study Protocol"],"prefix":"10.2739","volume":"66","author":[{"given":"AKIKO","family":"KADA","sequence":"first","affiliation":[{"name":"Clinical Research Center, National Hospital Organization Nagoya Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JUN","family":"TOHYAMA","sequence":"additional","affiliation":[{"name":"Department of Child Neurology, National Hospital Organization Nishi-Niigata Chuo National Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIDEAKI","family":"SHIRAISHI","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUKITOSHI","family":"TAKAHASHI","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, National Epilepsy Center, National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EIJI","family":"NAKAGAWA","sequence":"additional","affiliation":[{"name":"Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOMOYUKI","family":"AKIYAMA","sequence":"additional","affiliation":[{"name":"Department of Child Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AKIKO M","family":"SAITO","sequence":"additional","affiliation":[{"name":"Clinical Research Center, National Hospital Organization Nagoya Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUSHI","family":"INOUE","sequence":"additional","affiliation":[{"name":"National Epilepsy Center, National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MITSUHIRO","family":"KATO","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1445","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Taylor DC, Falconer MA, Bruton CJ, and Corsellis JA. Focal dysplasia of the cerebral cortex in epilepsy. J Neurol Neurosurg Psychiatry 1971; 34:369-387.","DOI":"10.1136\/jnnp.34.4.369"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fauser S, Huppertz HJ, Bast T, Strobl K, Pantazis G et al. Clinical characteristics in focal cortical dysplasia: a retrospective evaluation in a series of 120 patients. Brain 2006; 129:1907-1916.","DOI":"10.1093\/brain\/awl133"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Palmini A, Najm I, Avanzini G, Babb T, Guerrini R et al. Terminology and classification of the cortical dysplasias. Neurology 2004; 62:S2-S8.","DOI":"10.1212\/01.WNL.0000114507.30388.7E"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Blumcke I, Thom M, Aronica E, Armstrong DD, Vinters HV et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 2011; 52:158-174.","DOI":"10.1111\/j.1528-1167.2010.02777.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wagner J, Urbach H, Niehusmann P, von Lehe M, Elger CE et al. Focal cortical dysplasia type IIb: completeness of cortical, not subcortical, resection is necessary for seizure freedom. Epilepsia 2011; 52:1418-1424.","DOI":"10.1111\/j.1528-1167.2011.03158.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fauser S, Essang C, Altenmuller DM, Staack AM, Steinhoff BJ et al. Long-term seizure outcome in 211 patients with focal cortical dysplasia. Epilepsia 2015; 56:66-76.","DOI":"10.1111\/epi.12876"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Najm IM, Tassi L, Sarnat HB, Holthausen H, Russo GL. Epilepsies associated with focal cortical dysplasias (FCDs). Acta Neuropathol 2014; 128:5-19.","DOI":"10.1007\/s00401-014-1304-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Urbach H, Scheffler B, Heinrichsmeier T, von Oertzen J, Kral T et al. Focal cortical dysplasia of Taylor\u2019s balloon cell type: a clinicopathological entity with characteristic neuroimaging and histopathological features, and favorable postsurgical outcome. Epilepsia 2002; 43:33-40.","DOI":"10.1046\/j.1528-1157.2002.38201.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R et al. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 2012; 74:41-48.","DOI":"10.1016\/j.neuron.2012.03.010"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 2012; 44:941-945.","DOI":"10.1038\/ng.2329"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lim JS, Kim WI, Kang HC, Kim SH, Park AH et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat Med 2015; 21:395-400.","DOI":"10.1038\/nm.3824"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nakashima M, Saitsu H, Takei N, Tohyama J, Kato M et al. Somatic mutations in the MTOR gene cause focal cortical dysplasia type IIb. Ann Neurol 2015; 78:375-386.","DOI":"10.1002\/ana.24444"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Laplante M and Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-293.","DOI":"10.1016\/j.cell.2012.03.017"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hartford CM and Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007; 82:381-388.","DOI":"10.1038\/sj.clpt.6100317"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Zeng LH, Xu L, Gutmann DH, and Wong M. Rapamycin Prevents Epilepsy in a Mouse Model of Tuberous Sclerosis Complex. Ann Neurol 2008; 63:444-453.","DOI":"10.1002\/ana.21331"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M et al. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr 2014; 164:1195-1200.","DOI":"10.1016\/j.jpeds.2013.12.053"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Franz DN, Agricola K, Mays M, Tudor C, Care MM et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol 2015; 78:929-938.","DOI":"10.1002\/ana.24523"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 817-824.","DOI":"10.1016\/S0140-6736(12)61767-X"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Krueger DA, Care MM, Holland K, Agricola K, Tudor C et al. Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis. N Engl J Med 2010; 363:1801-1811.","DOI":"10.1056\/NEJMoa1001671"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013; 74:679-687.","DOI":"10.1002\/ana.23960"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. French JA, Lawson JA, Yapici Z, Ikeda H, Polster T et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388:2153-2163.","DOI":"10.1016\/S0140-6736(16)31419-2"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58:522-530.","DOI":"10.1111\/epi.13670"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Day S, Jonker AH, Lau LPL, Hilgers RD, Irony I et al. Recommendations for the design of small population clinical trials. Orphanet J Rare Dis 2018; 13:195.","DOI":"10.1186\/s13023-018-0931-2"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hilgers RD, Bogdan M, Burman CF, Dette H, Karlsson M et al. Lessons learned from IDeAl \u2014 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials. Orphanet Journal of Rare Diseases 2018; 13:77.","DOI":"10.1186\/s13023-018-0820-8"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Eichler HG, Bloechl-Daum B, Bauer P, Bretz F, Brown J et al. \u201cThreshold-crossing\u201d: A Useful Way to Establish the Counterfactual in Clinical Trials? Clin Pharmacol Ther 2016; 100:699-712.","DOI":"10.1002\/cpt.515"}],"container-title":["The Kurume Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/66\/2\/66_MS662007\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T04:38:33Z","timestamp":1627101513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/66\/2\/66_MS662007\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,30]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2739\/kurumemedj.ms662007","relation":{},"ISSN":["0023-5679","1881-2090"],"issn-type":[{"value":"0023-5679","type":"print"},{"value":"1881-2090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,30]]},"article-number":"MS662007"}}